10 news items
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI
3 Jun 24
®) and China. Karyopharm has a focused pipeline targeting indications
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
KPTI
3 Jun 24
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis
Karyopharm to Participate at the Jefferies Global Healthcare Conference
KPTI
29 May 24
. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
KPTI
9 May 24
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.
hcbipok5f47uygf7phei8e8egj4bjdvm8ki0gyp3wr73q2v42klkd
KPTI
8 May 24
) and China. Karyopharm has a focused pipeline targeting indications in multiple high
lmk xuqdy4539tjmmr07jsnbxweqlyt
KPTI
8 May 24
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell
nolpalawyrtr23l54ib0y6v9n40k hwmny86
KPTI
2 May 24
(as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma
pzg7uql57ivt1n4cs5d40dxg0 pxuqiukd7x4j8xr
KPTI
24 Apr 24
) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers
m3oz336ciw5hpky4fux38h5likqyx6vjsi6x
KPTI
1 Apr 24
) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications
- Prev
- 1
- Next